Bladder cancer (BCa) is one of the most common malignant tumors in the urinary system.
Developing effective prognostic gene and exploring the immune cells that affect the …

Bladder cancer is one of the most common malignant tumors of the urinary system that
seriously threatens the health of a population. In recent years, the application of …

Although immunotherapy has progressed in the treatment of bladder cancer, some patients
still have poor prognosis. New therapeutic targets are eager to be discovered to improve the …

Background We aimed to establish an immune-related gene (IRG) based signature that
could provide guidance for clinical bladder cancer (BC) prognostic surveillance. Methods …

Background: Bladder cancer (BLCA) ranks 10th in incidence among malignant tumors and
6th in incidence among malignant tumors in males. With the application of immune therapy …

Background Bladder cancer (BC) is the ninth most common malignant tumor. We
constructed a risk signature using immune-related gene pairs (IRGPs) to predict the …

A deeper understanding of the interaction between tumor cell and the immune
microenvironment in bladder cancer may help select predictive and prognostic biomarkers …

Bladder cancer (BLCA) is a common malignancy arising from the urinary bladder and
therapeutic options are limited. However, the mechanisms underlying BLCA development …

Background: To identify the immune-related genes of bladder cancer (BLCA) based on
immunological characteristics and explore their correlation with the prognosis. Methods: We …

Bladder cancer is one of the most common cancers worldwide. The immune response and
immune cell infiltration play crucial roles in tumour progression. Immunotherapy has …